A Sequential Scanning of the Immune Efficiency in Astrocytoma (Grade I to Grade III), Meningioma and Secondary Glioma Patients with and without Therapeutic Scheduling

REFERENCES

• Dix A. R., Brooks W. H., Roszman T. L., Morford L. A. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol. 1999; 100: 216–232, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bodmer S., Strommer K., Frei K., Siepl C., de Tribolet N., Heid I., et al. Immunosuppression and transforming growth factor-beta in glioblastoma. referential production of transforming growth factor-beta 2. J. Immunol. 1989; 43: 3222–3229, [CSA]
   Google Scholar
• Bodmer S., Huber D., Heid I., Fontana A. Human glioblastoma cell derived transforming growth factor-beta 2: Evidence for secretion of both high and low molecular weight biologically active forms. J Neuroimmunol. 1991; 34: 33–42, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• De Martin R., Haendler B., Hofer-Warbinek R., Gaugitsch H., Wrann Schlusener H., Seifert J. M., et al. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J. 1987; 6: 3673–3677, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fontana A., Hengartner H., de Tribolet N., Weber E. Glioblastoma cells release Interleukin 1 and factors inhibiting interleukin2-mediated effects. J Immunol. 1984; 132: 1837–1844, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kuppner M. C., Hamou M. F., Sawamura Y., Bodmer S., de Tribolet N. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J. Neurosurg. 1989; 71: 211–217, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Siepl C., Bodmer S., Frei K., MacDonald H. R., De Martin R., Hofer E., et al. The glioblastoma-derived, T cell suppressor factor transforming growth factor-beta 2 inhibits, T.; cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J. Immunol. 1988; 18: 593–600, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wrann M., Bodmer S., de Martin R., Siepl C., Hofer-Warbinek R., Frei K., et al. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J. 1987; 6: 1633–1636, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Castelli M. G., Chiabrando C., Fanelli R., Martelli L., Butti G., Gaetani P., et al. Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res. 1989; 49: 1505–1508, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Couldwell W. T., DoreDuffy P., Apuzzo M. L., Antel J. P. Malignant glioma modulation of immune function: Relative contribution of different soluble factors. J Neuroimmunol. 1991; 33: 89–96, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bogdan C., Nathan C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann. NY Acad. Sci. 1993; 685: 713–739, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ding L., Shevach E. M. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol. 1992; 148: 3133–3139, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fiorentino D. F., Zlotnik A., Vieira P., Mosmann T. R., Howard M., Moore K. W., et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 1991; 46: 3444–3451, [CSA]
   Google Scholar
• Taga K., Tosato G. IL-10 inhibit human T cell proliferation and IL-2 production. J. Immunol. 1992; 148: 1143–1148, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Merritt W. D., Bailey J. M., Pluznik D. H. Inhibition of interleukin-2-dependent cytotoxic T-lymphocyte growth by gangliosides. Cell Immunol. 1984; 89: 1–10, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Offner H., Thieme T., Vandenbark A. A. Gangliosides induce selective modulation of CD4 from helper, T.; lymphocytes. Immunol. J. 1987; 139: 3295–3305, [CSA]
   PubMed Web of Science ®Google Scholar
• Nidus Information Services, Inc., 41 East 11th Street, 11th Floor, New York, NY 10003 or emailoffice@well–connected.com or on the internet at www.well-connected.com
   Google Scholar
• DeAngelis L. M. Brain Tumors. The New England J. of Med. 2001; 344(2)114–123, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stahnke K., Simone F., Friesen C., Straub G., Debatin K. M. Activation of apoptosis pathways in peripheral blood lymphocytes in in vivo chemotherapy. Neoplasia 2001; 98(10)3066–3073, [CSA]
   Google Scholar
• Louagie H., Van Eijkeren M., Philippe L., Thierens H., Ridder de L. Changes in peripheral blood lymphocyte subsets in patients undergoing radiotherapy. Int. J. of Radiation. Biol. 1999; 75(6)767–771, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Willams J. L., Patchen M. L., Darden J. H., Jackson W. E. Effects of radiation on survival and recovery of T lymphocyte subsetw in C3H/HeN mice. Exp. Hematol. 1994; 22(6)510–516, [CSA]
   PubMed Web of Science ®Google Scholar
• Schedule Y. Indian Drug and Cosmetic Law. 1940, (amended version, 2005), Website: www.cdsco.nic.in
   Google Scholar
• Good clinical Practice, Central Drugs standard Control Organization. Directorate General of Health Services, Ministry of Health & Family Welfare, Govt. of India, Drug Controller General, New DelhiIndia
   Google Scholar
• Mukherjee J., Sarkar S., Ghosh A., Duttagupta A. K., Chaudhuri S. Chaudhuri Swapna. Immunotherapeutic effects of T11TS/SLFA-3 against nitrosocompound mediated neural genotoxicity. Tox. Lett. 2004; 150(3)239–257, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mukherjee J., Sarkar S., Begurn Z., Dutta S., Ghosh A., Chaudhuri S. Chaudhuri, Swapna. Preclinical changes in immunoreactivity and cellular architecture during the progressive development of intracranial neoplasm and its immunotherapeutic schedule with a novel biological response modifier, the T11TS/S-LFA-3. Asian Pacific J. Cancer Prevention 2002; 3: 325–337, [CSA]
   PubMedGoogle Scholar
• Sarkar S., Begum Z., Dutta S., Chaudhuri S. Chaudhuri Swapna. Sheep form of Leucocyte Function Antigen-3 (T IITS) exerts immunostimulatory and anti-tumor activity against experimental brain tumor: A new approach to biological response modifier therapy. J. Exp. Clin. Cancer Res. 2002; 21(1)95–106, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mackall C.-L., Fleisher T.-A., Brown M.-R., et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84: 2221–2228, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mackall C.-L., Hakim F.-T., Gress R.-E. Restoration of T cell homeostasis after T cell depletion. Semin Immunol 1997; 9: 339–346, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Brooks W. H., Netsky M. G., Normansell D. E., Horwitz D. A. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J. Exp. Med. 1972; 136: 1631–1647, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mahaley M. S., Jr., Brooks W. H., Roszman T. L., Bigner D. D., Dudka L. Ialyllactotetraosylceramide, a ganglioside marker for human malignant gliomas. J. Neurochem. 1988; 50: 912–919, [CSA]
   PubMed Web of Science ®Google Scholar
• Young H. F., Kaplan A. M. Cellular immune deficiency in patients with glioblastoma. Surg. Forum. 1976; 27: 476–478, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Brooks W. H., Roszman T. L., Mahaley M. S., Woosley R. E. Immunobiology of primary intracranial tumours: II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. Clin. Exp. Immunol. 1977; 29: 61–66, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mizoguchi H., O'Shea J. J., Longo D. L., Loeffler C. M., McVicar D. W., Ochoa A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258: 1795–1798, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gratas C., Tohma Y., Van Meir E. G., Klein M., Tenan M., Ishii N., Tachibana O., Kleihues P., Ohgaki H. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 1997; 7: 863–869, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Saas P., Walker P. R., Hahne M., Quiquerez A. L., Schnuriger V., Perrin G. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?. J. Clin. Invest. 1997; 99: 1173–1178, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Weller M., Weinstock C., Will C., Wagenknecht B., Dichgans J., Lang F., Gulbins E. CD95-dependent, T cell killing by glioma Cells expressing CD95 ligand: more on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain. Cell Physiol. Biochem. 1997; 7: 282–288, [CSA]
   Web of Science ®Google Scholar
• Weller M., Kleihus P., Dichgans J., Ohgaki H. CD95 ligand: Lethal weapon against malignant glioma. Brain Pathology. 1998; 8: 285–293, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hong J. H., Chiang C. S., Campbell I. L., Sun J. R., Withers H. R., McBride W. H. Induction of acute phase gene expression by brain irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1995; 33: 619–626, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Plevova P. Radiotherapy and chemotherapy-induced normal tissue damage: the role of cytokines and adhesion molecules. Radiol. Oncol. 2002; 36(2)109–119, [CSA]
   Google Scholar
• Schwaighofer H., Kernan N. A., O'Reilly R. J., Brankova J., Nachbaur D., Herold M., et al. Serum levels of cytokines and secondary messages after T-cell-depleted and non-T-cell-depleted bone marrow transplantation: influence of conditioning and hematopoietic reconstitution. Transplantation 1996; 62: 947–953, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sigurdson J. A., Jones I. M. Second cancers after radiotherapy: any evidence for radiation induced genomic instability. Oncogene. 2003; 22: 7018–7027, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pardoll D. T. cells and tumors. Nature, 411: 1010–1012, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Plunkett M. L., Sanders M. E., Selvaraj P., et al. Rosetting of activated human, T.; lymphocytes with autologous erythrocytes. Definition of the receptor and ligand molecules as CD2 and lymphocyte function associated antigen 3 (LFA-3). J. Exp. Med. 1987; 165: 664–676, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Raha S. K., Dey S. K., Roy S. K. Antitumor activity of Lasparaginase from Cylindrocarpon obstutisporum MB10 and its effect on the immune system. Biochem. Int. 1990; 21: 987–1000, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar